Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment - Wikidata - wikimedia - TriplyDB

Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment

Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment

http://www.wikidata.org/entity/Q36887659

about

ACTIVITY OF TRASTUZUMAB-EMTANSINE (TDM1) IN HER2-POSITIVE BREAST CANCER BRAIN METASTASES: A CASE SERIES.The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation.Central nervous system relapse in patients with untreated HER2-positive esophageal or gastroesophageal junction adenocarcinoma.Closing the gap: astrocytes and brain metastasis Trastuzumab distribution in an in-vivo and in-vitro model of brain metastases of breast cancer.Trastuzumab emtansine: determining its role in management of HER2+ breast cancer.Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review.MicroRNA-378 enhances radiation response in ectopic and orthotopic implantation models of glioblastoma.A cerebellar window for intravital imaging of normal and disease states in mice.Drug resistance in HER2-positive breast cancer brain metastases: blame the barrier or the brain?Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases.Liquid biopsy for HER2-positive breast cancer brain metastasis: the role of the cerebrospinal fluid.Shortwave infrared fluorescence imaging with the clinically approved near-infrared dye indocyanine green

P2860

Q36825346-9AB9B239-FBDB-48B6-AF9C-2EECF382504F Q38766447-1D5ABB78-E14F-44DE-BCC0-EC715ABA1E13 Q39751816-D73166BE-6C8B-434B-889A-856E462D718C Q41162193-3C20155F-FD85-45E4-923F-47387D691F43 Q45072965-0E9E652D-8285-46D3-86B5-1EAB42A9D57C Q47795804-7C3C4FF6-1660-4752-A5D5-D8CFD7A27149 Q47839509-0E6826BE-73C8-4DA5-B2F8-BA74BD23192C Q47996105-259C7E58-A6B5-4312-852A-9EB6A1E0C22F Q48032985-6E2FEC2C-602E-45E4-A34E-C01717376192 Q50043843-546B9F5D-3DE0-414D-A0BB-EAAC3CDAC8F3 Q55100041-7055CFED-2A12-443F-94EB-485B94CF0BEA Q55340002-D508575C-0A4D-42F4-826F-386729503976 Q57352904-B634D7C6-C93C-4590-BC6D-FD621EAA4E4A

P2860

Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment

http://www.wikidata.org/entity/Q36887659

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment

@en

type

label

Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment

@en

prefLabel

Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment

@en

P1433

Q36887659-3A0FF184-DA81-4FED-ABE0-4AAA63446D05

P1476

Q36887659-2C54E331-36ED-40B4-B988-BCB08AF689F9

P2093

Q36887659-08DCCA2C-C150-4BCB-998D-E4D71753A14A

Q36887659-1A266185-6C49-4816-8D16-60FD9767DC32

Q36887659-4566DA93-7857-45BC-8B87-621066F60471

Q36887659-463C8ACB-A72D-4DFF-902D-0D7A91FF7368

Q36887659-89E6115D-99EA-44FD-9E97-E8555C47A3AE

Q36887659-8C3D7565-7BD4-4C60-B682-3FC09D63D7B7

Q36887659-A76904F6-108F-408F-941F-826B4548BFF4

Q36887659-B08A2DD9-2D03-4C85-BE94-472FA9A9C371

Q36887659-BBC81A0B-6F4C-48CC-97E2-FFB5DBD7C20C

Q36887659-C3C73DDE-BA9F-4196-BABD-3EAB1EEAFBD5

P2860

Q36887659-067F3477-2BC5-4469-BE95-843E83936923

Q36887659-0AB270D0-5D5A-46C1-A97F-C7E583D12F16

Q36887659-0E00ED92-494A-4FB4-AF08-AFC87B9BDD97

Q36887659-1BEE4B6E-13F9-42F3-8E05-CC5B2B6ED74B

Q36887659-248CB806-160F-40B4-8982-4B6015DCD099

Q36887659-3788D6FF-0549-4B19-9E9D-9969D17A0C0A

Q36887659-42925FCC-78B9-40F4-8730-8E65AD99C3DB

Q36887659-571DACF7-0932-4BCE-938A-ED77AE78BA3B

Q36887659-5EE6AB75-A2D5-4C79-BB88-6E96758C37B7

Q36887659-711658CB-100B-4AD7-90AE-81E0ADDC7837

P31

Q36887659-D17B850A-65C8-4F4D-A927-73B4ECBD958B

P356

Q36887659-DC56CC28-36EE-4BF0-B654-148B78B1E781

P407

Q36887659-3C8312BF-2E0B-4BE2-B377-D0881B5C155A

P433

Q36887659-EA90604F-3ED5-4365-A006-D4900F32F48D

P478

Q36887659-C5EFCA08-D371-4A8C-9777-BEFB78A4ADE0

P50

Q36887659-70EA7EEA-B559-44B9-A804-0797B3DB425A

Q36887659-83FDA45C-8274-43EB-BF55-15ECB7F933C2

Q36887659-8BFA4651-76CB-4EE4-A5E5-CBBB619C409E

Q36887659-91557982-102C-48FB-8917-0A652298260F

Q36887659-B9F1FC61-5524-4500-8EE1-D1F186E13E50

P577

Q36887659-31BDD08B-6C1A-41C8-9346-ED500CC56923

P5875

Q36887659-9DD7BB26-4E4E-4BA4-9738-3DA0B1D4E645

P698

Q36887659-C0FC2BC5-9053-4E91-B66E-6AF8F1AE2969

P932

Q36887659-BE5613DF-7859-4A55-A9CE-4090096A6AD7

P356

P1433

Journal of the National Cancer Institute

P1476

Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment

@en

P2093

Dai Fukumura

http://www.w3.org/2001/XMLSchema#string

Dan G Duda

http://www.w3.org/2001/XMLSchema#string

David P Kodack

http://www.w3.org/2001/XMLSchema#string

Elena Brachtel

http://www.w3.org/2001/XMLSchema#string

Gino B Ferraro

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Engelman

http://www.w3.org/2001/XMLSchema#string

Jonas Kloepper

http://www.w3.org/2001/XMLSchema#string

Mark Badeaux

http://www.w3.org/2001/XMLSchema#string

Martin K Selig

http://www.w3.org/2001/XMLSchema#string

Peigen Huang

http://www.w3.org/2001/XMLSchema#string

P2860

Trastuzumab emtansine for HER2-positive advanced breast cancer.

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.

Trastuzumab--mechanism of action and use in clinical practice

Brain metastases from breast cancer: lessons from experimental magnetic resonance imaging studies and clinical implications.

Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline.

Real-time imaging reveals the single steps of brain metastasis formation.

Activity of T-DM1 in HER-2 positive central nervous system breast cancer metastases

The blood-brain barrier and cancer: transporters, treatment, and Trojan horses.

Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study.

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.

P31

scholarly article

P356

10.1093/JNCI/DJV313

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

108

http://www.w3.org/2001/XMLSchema#string

P50

Kamila Naxerova

Ram C Shankaraiah

P577

2015-11-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

283577442

http://www.w3.org/2001/XMLSchema#string

P698

26547932

http://www.w3.org/2001/XMLSchema#string

P932

4862418

http://www.w3.org/2001/XMLSchema#string